Navigation Links
Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
Date:2/28/2011

r this post-acute indication. Before the end of the second quarter of 2011, Nile plans to file a new Investigational New Drug (IND) application and to initiate a Phase I pharmacokinetics and pharmacodynamics (PK/PD) clinical trial. Following the PK/PD trial, Nile intends to initiate a Phase II double-blind, placebo-controlled, dose-ranging clinical trial in post-acute heart failure patients in the first half of 2012.  

"This new path represents the identification of an opportunity that incorporates the current clinical, scientific, and regulatory perspectives on the development of heart failure therapeutics," said James Young, MD, Professor and Executive Dean, Cleveland Clinic Lerner College of Medicine. "Preclinical and clinical data have shown that the natriuretic peptide class can act on multiple disease processes that play a role in the negative outcomes associated with heart failure.  The unique properties of cenderitide provide a sound rationale to support this innovative strategy and could lead to the development of a differentiated product with clinically meaningful benefits."

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel, rationally designed chimeric peptide for the treatment of heart failure, and CU-NP, a second novel, rationally designed natriuretic peptide.  

More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of hist
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
2. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
3. Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
4. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
5. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
6. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
7. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
8. Echo Therapeutics Announces Appointments to Board of Directors
9. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
11. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The Eastern European medical device ... providers as well as new medical-device manufacturers are constantly ... looking at ways to reduce the cost incurred for ... one of the effective means to achieve this target. ... in Eastern European and provides profiles of key distributors ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
(Date:9/30/2014)... , September 30, 2014 In ... CSF (Cerebrospinal Fluid) backflow of the Eldor spinal needle ... the single hole pencil point spinal needles of the ... Spinal anesthesia is an excellent type of ... Urology, General Anesthesia, etc. It is estimated ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... DIEGO, March 24 Calixa Therapeutics Inc. today announced ... CXA-101, a novel cephalosporin antibiotic with excellent in ... Phase 1 study demonstrated that CXA-101 was well tolerated, ... that of marketed cephalosporin antibiotics. No dose-limiting toxicity was ...
... ClinicROCHESTER, Minn., March 23 Here are highlights ... Clinic,s research magazine. You may cite and link ... Reprinting is allowed with proper attribution. Please include ... permit: Visit http://discoverysedge.mayo.edu for subscription information.Parkinsonism: ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... 2014(BRONX, NY)Medications are the leading cause of allergy-related sudden ... death certificates from 1999 to 2010, conducted by researchers ... Albert Einstein College of Medicine of Yeshiva University . ... of Allergy and Clinical Immunology , also found that ... high among older people and African-Americans and that such ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... small Gram-negative spiral rods. Campylobacter jejuni ( ... water, milk and meat, especially chicken, is one of ... its mode of pathogenesis is not clear. , A ... in the World Journal of Gastroenterology addresses ...
... China Medical Technologies,Inc. (the "Company") (Nasdaq: ... device,company that develops, manufactures and markets advanced ... has completed the previously,announced sale of its ... (the "HIFU Business") to Chengxuan International Ltd. ...
... 30 Cardium Therapeutics,(NYSE Alternext US: CXM) reported ... indicating that the company is currently considered to ... Alternext US LLC,(formerly the American Stock Exchange). ... which was filed on November 10, 2008, noncompliance ...
... CAMBRIDGE, Mass., Dec. 30 Biopure Corporation (Nasdaq: ... has advised the U.S. Naval Medical Research Center ("NMRC") by ... Biopure,s product Hemopure [hemoglobin glutamer - 250 (bovine)], under a ... As previously announced, the Navy had filed a protocol ...
... repair genes initially appeared to be statistically significantly associated ... from individual studies are pooled, however, few DNA repair ... according to a field synopsis published in the December ... National Cancer Institute. , Because DNA damage is ...
... WLP ) will,release fourth quarter 2008 financial results ... Management will review these results and its,outlook during a conference ... should be accessed at least 15 minutes prior to its ... (Domestic) ...
Cached Medicine News:Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 3Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 4Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 5Health News:U.S. Navy Requested Operations Trial on FDA Hold 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 3Health News:Few DNA repair genes maintain association with cancer in field synopsis 2Health News:WellPoint to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 28, 2009 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: